Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $303

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $298 to $303.